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Recent innovations have the potential to improve rhythm control therapy in patients with atrial fibrillation (AF). Controlled trials provide
new evidence on the effectiveness and safety of rhythm control therapy, particularly in patients with AF and heart failure. This review
summarizes evidence supporting the use of rhythm control therapy in patients with AF for different outcomes, discusses implications for
indications, and highlights remaining clinical gaps in evidence. Rhythm control therapy improves symptoms and quality of life in patients
with symptomatic AF and can be safely delivered in elderly patients with comorbidities (mean age 70 years, 3–7% complications at 1 year).
Atrial fibrillation ablation maintains sinus rhythm more effectively than antiarrhythmic drug therapy, but recurrent AF remains common,
highlighting the need for better patient selection (precision medicine). Antiarrhythmic drugs remain effective after AF ablation, underpin-
ning the synergistic mechanisms of action of AF ablation and antiarrhythmic drugs. Atrial fibrillation ablation appears to improve left ven-
tricular function in a subset of patients with AF and heart failure. Data on the prognostic effect of rhythm control therapy are heteroge-
neous without a clear signal for either benefit or harm. Rhythm control therapy has acceptable safety and improves quality of life in
patients with symptomatic AF, including in elderly populations with stroke risk factors. There is a clinical need to better stratify patients
for rhythm control therapy. Further studies are needed to determine whether rhythm control therapy, and particularly AF ablation,
improves left ventricular function and reduces AF-related complications.
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The prevalence of atrial fibrillation (AF) and its associated mortality
and morbidity are expected to double or triple within the next two
to three decades, driven by population ageing and increased inci-
dence of AF.1,2 Even on optimal anticoagulation and rate control
therapy, patients with AF are at high risk of cardiovascular death, par-
ticularly sudden death and death due to heart failure.3,4 Rhythm con-
trol therapy using antiarrhythmic drugs, cardioversion, and AF
ablation, is clinically used to improve AF-related symptoms.5
Currently, there is no established indication for rhythm control ther-
apy apart from improvement of AF-related symptoms.6–8 The
CABANA (Catheter Ablation vs. Anti-arrhythmic Drug Therapy for
Atrial Fibrillation) trial recently provided new confirmation on the
safety of AF ablation in contemporary AF patients at risk of stroke.9
The smaller CASTLE-AF (Catheter Ablation vs. Standard Conven-
tional Therapy in Patients with Left Ventricular Dysfunction and
Atrial Fibrillation) suggests that AF ablation could improve outcomes
in patients with AF and severe heart failure compared to drug ther-
apy, combining rate control therapy and antiarrhythmic drug ther-
apy.10 Here, we review the available evidence supporting the use of
rhythm control therapy in patients with AF, discuss potential implica-
tions for indications, and highlight clinical evidence gaps.
Rhythm control therapy improves
atrial fibrillation-related
symptoms
Restoring and maintaining sinus rhythm indicated to minimize symp-
toms is a main goal in patients who remain symptomatic despite ad-
equate rate control.11,12 Interestingly, the effects of rhythm control
on quality of life are less uniform than their clear effects on maintain-
ing sinus rhythm (Table 1). Both natural variation in patient-reported
quality of life, imprecise instruments to assess quality of life, and vari-
able effects of rhythm control therapy on quality of life in individual
patients can explain this heterogeneity.13,14 The European Heart
Rhythm Association (EHRA) symptom score was introduced in 2007
as a simple clinical tool to quantify AF-related symptoms,15 with sub-
sequent refinement and validation.16 Several disease-specific instru-
ments are available, all with specific strengths and limitations.17 In
addition, perceived AF-related symptoms may not always be due to
AF, and concomitant cardiovascular diseases and risk factors may af-
fect patient’s health perception in addition to the arrhythmia it-
self.18,19 Furthermore, patients with paroxysmal AF can be expected
to report variable quality of life depending on their rhythm at the
time of assessment, on their ability to memorize past symptoms dur-
ing clusters of AF episodes, and by anxiety related to future episodes
of AF.
Effectiveness and safety of rhythm
control therapy
The success of rhythm control therapy depends on multiple factors
including the number, type, and severity of underlying conditions, age,
gender, adherence to antiarrhythmic drug therapy, and factors
related to the quality of the AF ablation procedure.2,8,20 Furthermore,
AF recurrence rates depend on the intensity of electrocardiogram
(ECG) monitoring and duration of follow-up.15 Thus, comparing ab-
solute recurrence rates between studies and comparisons to histor-
ical controls can be misleading (Table 1).
Effectiveness and safety of
antiarrhythmic drug therapy
On average, antiarrhythmic drugs double the proportion of patients
who maintain sinus rhythm. Amiodarone is more effective than other
antiarrhythmic drugs in maintaining sinus rhythm, and catheter abla-
tion is more effective than antiarrhythmic drugs.8 The long-term
complication rates of antiarrhythmic drug therapy are comparable to
complications in patients treated with AF ablation.9,21 Although amio-
darone has been associated with adverse outcomes in non-random-
ized analyses of patients at very high risk,22 the safety of
antiarrhythmic drug therapy found in recent randomized trials in
patients with AF attenuates historical safety concerns,9,21 particularly
in patients with heart failure.23 Unlike earlier trials of antiarrhythmic
drugs compared to placebo or rate control therapy (Table 1),23–25
antiarrhythmic drug therapy with dronedarone was associated with
reduced cardiovascular hospitalizations and cardiovascular deaths
compared to placebo.26 The same substance, dronedarone, used as a
rate-controlling agent, was associated with higher rates of heart fail-
ure, stroke, and cardiovascular death in patients with permanent AF
in the PALLAS trial.27 Patients included in PALLAS were not consid-
ered suitable for rhythm control therapy, did not receive interven-
tions to restore sinus rhythm (e.g. cardioversion, AF ablation) and
had severe heart failure. Hence, they were deprived of any potential
to benefit of sinus rhythm. Patients treated with dronedarone in
ATHENA, in contrast, received that therapy to restore sinus rhythm.
Taken together, these data may suggest that the beneficial effects
found in ATHENA could be associated with its rhythm controlling ef-
fect, but more data are needed.
Antiarrhythmic drugs are also effective after AF ablation. Two re-
cent randomized studies (AMIO-CAT28 and POWDER-AF29)
showed that adding antiarrhythmic drug therapy to AF ablation
improves sinus rhythm maintenance for the duration of therapy. This
synergistic effect of antiarrhythmic drugs with AF ablation reflects the
common (approximately 50% of patients) use of antiarrhythmic
drugs 1 year after AF ablation.30 A substudy within AMIO-CAT meas-
uring brain natriuretic peptide suggested that biomarkers may im-
prove identification of patients at risk for recurrent AF,31 pointing
potentially towards personalized or stratified selection of patients for
specific rhythm control therapies.32
Effectiveness and safety of atrial
fibrillation ablation
Initially evaluated in young patients with highly symptomatic AF
(mean age around 55 years) who were refractory to antiarrhythmic
drug therapy, AF ablation maintains sinus rhythm better than
antiarrhythmic drugs.33,34 This was confirmed in CABANA.9 A






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































meta-analysis of randomized trials (6167 patients) found that AF abla-
tion achieves freedom from recurrent AF in approximately half of the
patients [53% (46–60), mean (95% confidence interval, CI)], with
slightly higher recurrence rates in patients with chronic forms of
AF.35 Periprocedural complications occur in ca. 5% of patients (7.8%
in EORP AF ablation, 4.8% in CABANA), including tamponade (ca.
1%), stroke, or transient ischaemic attack (ca. 0.5–1% in anticoagu-
lated patients), access site complications (ca. 2–3%), and death
(<1%).30,36–38 Reablation is performed in 20–50% of patients under-
going a first AF ablation. During long-term follow-up for up to
10 years, up to 60% of AF ablation patients remain free of clinically
relevant recurrences of AF (with around three-fourths in sinus
rhythm after 1 year), and approximately half of these patients receive
combination therapy with antiarrhythmic drugs.39–41 Whether add-
itional ablation strategies improve these outcomes needs to be
investigated.42
Atrial fibrillation ablation
compared to antiarrhythmic drug
therapy after CABANA
CABANA was designed to test whether AF ablation can reduce mor-
tality compared to antiarrhythmic drugs in patients with AF in need
for rhythm control therapy and with stroke risk factors.43 In early
2013, a planned, blind data review identified slow enrolment and
lower event rates than anticipated. This resulted in a change in pri-
mary endpoint from all-cause mortality to a composite of death, dis-
abling stroke, serious bleeding, or cardiac arrest. In addition, the
sample size was reduced. The results have just been reported9: Of
the 2204 patients randomized (median age, 68 years; 37% female;
57% persistent AF), 89.3% completed the trial. In patients random-
ized to AF ablation, 91% underwent the procedure, while AF ablation
was performed in 27.5% of the patients randomized to drug therapy,
in line with expectations at the start of the trial.43 Safety of rhythm
control therapy was good in this elderly patient population (mean
age 68 years), with low complication rates in both arms: Patients
randomized to AF ablation experienced tamponade (0.8%), haemato-
mas (2.3%), and pseudoaneurysms (1.1%). Patients randomized to
antiarrhythmic drug therapy experienced thyroid disorders (1.6%)
and proarrhythmia (0.8%). The primary outcome was not different
between groups.9 Over a median follow-up of 48.5 months, the pri-
mary endpoint occurred in 8.0% of patients randomized to AF abla-
tion, and in 9.2% of patients randomized to antiarrhythmic drug
therapy [hazard ratio (HR) 0.86, 95% CI 0.65–1.15; P= 0.30]. Key sec-
ondary outcomes were not different between random groups,
including all-cause mortality was 5.2% and 6.1% (HR 0.85, 95% CI
0.60–1.21; P= 0.38), death or cardiovascular hospitalization rates
were 51.7% and 58.1% for (HR 0.83, 95% CI 0.74–0.93; P= 0.001).
Recurrent AF was less common in patients randomized to AF abla-
tion in the subgroup of 1240 patients undergoing systematic ECG
monitoring (HR 0.52, 95% CI 0.45–0.60; P< 0.001). Both treatment
groups showed improved quality of life, as assessed by the Atrial
Fibrillation Effect on Quality of Life (AFEQT) summary score and the
Mayo AF-Specific Symptom Inventory (MAFSI). Patients randomized
to catheter ablation showed a greater improvement in quality of life
(mean difference of 5.3 points).44 This greater effect of AF ablation
on quality of life is consistent with the main finding of the Swedish
CAPTAF trial.45
Similar to other observational data sets, on-treatment analysis sug-
gested improved outcomes in patients undergoing AF ablation. These
findings are additionally supported by a recent study using a large US
administrative database of routine patient data, analysing patients who
meet the CABANA inclusion criteria.46 Unknown and known con-
founders, censoring of events—either intentionally by study design or
unintentionally because of loss to follow-up—, self-selection of low
risk patients to cross over to ablation, and immortal time bias are
some of the sources of bias that can explain these findings.47
Rhythm control therapy in
patients with atrial fibrillation and
heart failure
Atrial fibrillation and heart failure (AFþHF) frequently coexist and
this is associated with high morbidity and mortality.48 To improve
outcomes, restoring and maintaining sinus rhythm has been proposed
in patients with AFþHF. Amiodarone is the only antiarrhythmic drug
with sufficient safety data in patients with reduced left ventricular
ejection fraction.8 Large randomized trials of antiarrhythmic drugs
compared to rate control in patients with AFþHF did not find differ-
ences in all-cause mortality, cardiovascular mortality, or heart failure
hospitalizations.23,49,50 Likewise, patients who maintain sinus rhythm
(‘successful rhythm control therapy’) did not have better survival
than those with recurrent AF.50 Several small case series and con-
trolled trials found that patients undergoing AF ablation have
improved left ventricular function, often using echocardiography to
assess left ventricular (LV) function (Table 2): four out of five relative-
ly small studies found improved left ventricular function in patients
with AFþHF randomized to AF ablation (Table 2),51–59 largely seen in
trials that assessed left ventricular function by echocardiography,
which is less reliable in AF than in sinus rhythm.60 There were associ-
ated improvements in exercise capacity and brain natriuretic peptide
(BNP) levels (Take home figure, bottom panel). Improved exercise
capacity and to some extent improved left ventricular function, but
not lower BNP, could be partially explained by bias in unblinded trials.
These effects have been extrapolated with a certain enthusiasm.61
The largest trial comparing AF ablation with ‘medical therapy’ (mostly
rate control, but including antiarrhythmic drugs) in patients with
AFþHF is CASTLE-AF (Table 2).10 The quality of rate control ther-
apy may have affected changes in LV function in the control group of
the published trials that used rate control as comparator. Thirty-four
of the 363 randomized patients were lost to follow-up despite an
implanted device allowing home monitoring. In the remaining
patients, catheter ablation reduced mortality and HF hospitalizations
(28.5% compared with 45%), but had no effect on all-cause hospital-
izations and stroke. Details of the drug therapy given to patients
randomized to ‘medical therapy’ have not been published. One-third
of the patients assigned to medical therapy were on antiarrhythmic
drugs at their final follow-up, 22% were in sinus rhythm at 60 months
(compared to 63% in the AF ablation arm, Table 2). In line with these
findings, the recent update of the AHA/ACC/HRS guidelines for AF





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































..included a Class IIb recommendation for AF ablation in patients with
heart failure. So far, there is no information about outcomes follow-
ing catheter ablation for AF in patients with heart failure and a pre-
served ejection fraction. Despite these limitations, CASTLE-AF and
the AATAC trial62 contribute evidence that selected patients with
AFþHF benefit from AF ablation (Table 2),51–59 but open questions
remain regarding selection of adequate patients and validity of the
findings in ‘all-comer’ patients. More research is needed to determine
the effect of AF ablation on cardiovascular outcomes in patients with
AFþHF.
Rhythm control therapy and
stroke
The clear association of AF and ischaemic stroke may suggest that
maintaining sinus rhythm can help to prevent strokes. There is no sig-
nal for reduced strokes in the earlier ‘rate vs. rhythm’ studies
(Table 1), including the reasonably large AF-CHF trial.23 There were
only three and seven disabling strokes in each arm in CABANA, with-
out differences between groups.9 Interestingly, in a post hoc analysis
of the ATHENA trial (Table 1), patients randomized to dronedarone
had a lower risk of stroke or transient ischaemic attack (1.2% vs.
1.8%).26 A retrospective, propensity-score matched analysis of a sub-
set of AF patients taken from the Swedish patient registry also sug-
gested that AF ablation may be associated with a lower incidence of
ischaemic stroke.63 This is similar to propensity-matched patient
comparisons in the largest health maintenance organization in Israel,
comparing 969 AF patients undergoing AF ablation to 3772 AF con-
trols.64 These analyses are prone to several biases, including known,
unmeasured and unknown confounders, and others.63
Rhythm control therapy and
cognitive decline
Atrial fibrillation is associated with cognitive dysfunction and demen-
tia. Anticoagulation appears to reduce dementia in patients with AF
in a nationwide cohort analysis.65 While it is unlikely that antiarrhyth-
mic drug therapy causes cerebral complications (stroke, transient is-
chaemic attack, or cognitive decline), there is a peri-procedural risk
of ischaemic stroke (0.3–1%) as well as a risk of magnetic resonance
imaging (MRI)-detected clinically silent ischaemic brain lesions in
patients undergoing AF ablation.37 This can increase brain damage
and subsequently lead to cognitive decline.37 Interestingly, the
AXAFA–AFNET 5 study found small MRI-detected brain lesions in
Take home ﬁgure AF ablation may affect cardiovascular outcomes (top panel) and appears to improve left ventricular function (bottom panel)
in selected patients with Atrial Fibrillation and Heart Failure. Further evidence is needed to underpin these hypothesis-generating findings.



































































































ca. 30% of patients undergoing a first AF ablation on continuous anti-
coagulation, but also detected an improved cognitive function as
assessed by Montreal Cognitive Assessment (MoCA) 3 months after
AF ablation.38
Rhythm control therapy may reduce AF-related stroke risk by
reducing AF burden and subsequent improvement in atrial cardiomy-
opathy,66 potentially reducing silent embolic lesions, and possibly
improving perfusion and metabolism of the brain. A large retrospect-
ive observational study found a lower rate of new-onset dementia in
4212 patients undergoing AF ablation compared to 16 848 non-
ablated AF patients, while a substudy in the randomized AFFIRM trial
did not find a difference in cognitive function between patients
randomized to rate or rhythm control therapy, while the AXAFA
study found improved cognitive function in 674 patients 3 months
after AF ablation compared to baseline.38 The possible cognitive ben-
efits of restoring sinus rhythm in AF patients can be attenuated by
atrial cardiomyopathy and by concomitant cardiovascular conditions
and other unknown confounders that can cause brain damage,
stroke, and cognitive dysfunction in the absence of AF.66,67
Unfortunately, neither CABANA nor CASTLE-AF reported cogni-
tive function outcomes. Ongoing research such as the case–control
DIAL-F cohort (NCT01816308) and the randomized EAST-AFNET
4 trial68 will provide further information on the impact of rhythm
control therapy including AF ablation on cognitive function.
Rhythm control therapy and atrial
cardiomyopathy
The term ‘atrial cardiomyopathy’ summarizes the structural, architec-
tural, contractile, or electrophysiological changes in diseased atria.66
Cardiovascular diseases (e.g. hypertension, heart failure, valvular
heart disease, ischaemic heart disease, or diabetes) but also ageing
can contribute to an atrial cardiomyopathy. Atrial fibrillation itself
accelerates the underlying disease processes, thus contributing to
atrial cardiomyopathy.69 Left atrial enlargement, a summative clinical
proxy for atrial cardiomyopathy, is partially reversed after AF abla-
tion.7,70,71 Early rhythm control therapy, including AF ablation, has
been suggested to slow these processes, thereby simplifying rhythm
control therapy and potentially improving long-term outcomes.68
Hence, early rhythm control therapy could slow atrial cardiomyop-
athy. However, this hypothesis requires confirmation in further stud-
ies and trials.
Summary and conclusions
Recent randomized trials and observational data sets including
CASTLE-AF and CABANA provide important reassurance on the
safety of rhythm control therapy in contemporary patients with AF,
including in elderly patients with concomitant cardiovascular diseases.
The data confirm the superior effectiveness of AF ablation compared
to antiarrhythmic drugs to restore and maintain sinus rhythm, and
demonstrate that antiarrhythmic drugs remain effective after AF abla-
tion. Several smaller studies suggest that AF ablation can improve left
ventricular function assessed by echocardiography in selected
patients with AF and heart failure. Further studies to investigate the
impact of rhythm control therapy on LV function in different, clearly
defined subsets of patients with AF are warranted. The effects of
rhythm control therapy on cardiovascular death, stroke, heart failure,
acute coronary syndromes, as well as secondary outcomes such as
left atrial, ventricular, and cognitive function require further research,
such as the on-going EAST–AFNET 4 trial.68
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